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US hospital discharges for which Clostridium difficile–
associated disease (CDAD) was listed as any diagnosis
doubled from 82,000 (95% confidence interval [CI]
71,000–94,000) or 31/100,000 population in 1996 to
178,000 (95% CI 151,000–205,000) or 61/100,000 in 2003;
this increase was significant between 2000 and 2003
(slope of linear trend 9.48; 95% CI 6.16–12.80, p = 0.01).
The overall rate during this period was severalfold higher in
persons >65 years of age (228/100,000) than in the age
group with the next highest rate, 45–64 years (40/100,000;
p<0.001). CDAD appears to be increasing rapidly in the
United States and is disproportionately affecting older per-
sons. Clinicians should be aware of the increasing risk for
CDAD and make efforts to control transmission of C. diffi-
cile and prevent disease.
C
lostridium difficile is an anaerobic, spore-forming
bacillus that produces 2 important exotoxins: toxin A,
an enterotoxin, and toxin B, which is primarily a cytotox-
in (1). C. difficile is the most commonly recognized cause
of antimicrobial drug–associated diarrhea. Although C.
difficile–associated disease (CDAD) is usually localized to
the large bowel, where it manifests as diarrhea and
pseudomembranous colitis, disease may progress to toxic
megacolon, sepsis with or without intestinal perforation,
and death (2) CDAD is increasingly recognized among
residents of long-term care facilities (3) and even among
persons living in the community (4); however, it most
commonly affects patients in short-stay hospitals, where
epidemic strains of C. difficile may be transmitted exten-
sively both within and between facilities (5,6). Moreover,
substantial excess healthcare costs and excess hospital
days are associated with CDAD among short-stay hospital
patients (7,8). 
Several reports from individual hospitals (9–11) and a
recent report primarily from the intensive care unit compo-
nent of the National Nosocomial Infection Surveillance
System (NNIS) (12) suggest that the incidence of CDAD
may be increasing. However, only 90 to 340 hospitals con-
tributed to NNIS during the study period, and these hospi-
tals do not represent a probability sample of all US
hospitals. Therefore, we analyzed national hospital dis-
charge data to determine 1) the scope and magnitude of
CDAD in US short-stay hospitals, 2) whether the rate of
CDAD was indeed increasing, and if so, 3) the epidemio-
logic factors associated with such an increase.
Methods
The National Hospital Discharge Survey (NHDS) is
conducted annually by the National Center for Health
Statistics, Centers for Disease Control and Prevention
(CDC), and consists of diagnosis and demographic data
collected from a national probability sample of patient
discharge records (13). At least 90% of a panel of 500 hos-
pitals participate, from which over 300,000 discharge
records are sampled each year. Based upon the analysis
weight applied to each record of this ≈1% sample, nation-
al estimates were made regarding the number and charac-
ter of all nonfederal, short-stay hospital discharges.
NHDS data were used to determine the number of dis-
charges with the International Classification of Diseases,
9th Revision, Clinical Modification (ICD-9-CM) code
(008.45) specific for “intestinal infection due to
Clostridium difficile” listed as a discharge diagnosis. This
code was introduced in 1993 and is the only ICD-9-CM
code specific for CDAD.
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charges with CDAD listed as a discharge diagnosis, the
proportions of discharges with CDAD, and the rates per
100,000 US population were determined for the years
1996–2003. Standard errors for all statistics were calculat-
ed by using SUDAAN version 7.0 (Research Triangle
Institute, Research Triangle Park, NC, USA), which takes
into account the complex sample design of the NHDS. A
description of the software and the approach it uses have
been published (14). Data were stratified according to
whether CDAD was listed as the first-listed vs. any-listed
diagnosis, patient sex, patient age, and hospital geograph-
ic region (according to US census regions), bed size, and
ownership type (i.e., proprietary, state and local govern-
ment, or nonprofit). The NHDS collects data on up to 7
diagnoses for each discharged patient sampled. The first-
listed diagnosis is the principal diagnosis if it were speci-
fied as such on the medical record or the face sheet of the
discharge summary of the patient. If the principal diagno-
sis is not specified, then diagnoses are listed in the order
they are given. The principal diagnosis is the condition
established after study as chiefly responsible for the hospi-
talization. Therefore, estimates for the first-listed diagno-
sis of CDAD refer to patients for whom CDAD is most
likely the primary reason for the hospital admission. Any
listed diagnosis estimates reflect discharged patients for
whom CDAD was either a primary or a secondary diagno-
sis, including those patients who may have contracted
CDAD during the current hospitalization, as well as those
who acquired it by other means. 
Rates of discharges with CDAD as any diagnosis over
the entire study period (i.e., 1996–2003) were compared
by various demographic factors using the 2-tailed Z-test
based on standard errors obtained from SUDAAN. Tests of
linear trend over time in rates, percentages, and numbers
were performed by using a weighted least-squares regres-
sion method; p values were determined from the t statistic
by using degrees of freedom equal to 1 less than the num-
ber of years over which trends were examined (15).
Because the trend in overall and stratified rates changed so
remarkably at the midpoint of the study period, separate
trend analyses were performed for 1996–1999 and
2000–2003. Although these separate trend analysis were
performed for all stratified rates presented, only the most
pertinent negative findings are presented, along with all
significant trend results (i.e., p<0.05). 
Results
From 1996 through 2003, an estimated 264,000 (95%
confidence interval [CI] 232,000–296,000) and 978,000
(95% CI 869,000–1,087,000) discharges for which CDAD
was listed as either first or as any diagnosis, respectively.
No significant trend was found in the numbers or rates of
discharges with CDAD listed as either the first or any diag-
nosis from 1996 to 1999. In contrast, the number of dis-
charges for which CDAD was listed as the first diagnosis
increased from 25,000 (95% CI 19,000–31,000) in 2000 to
54,000 (95% CI 41,000–  67,000) in 2003 (slope expressed
as the average change in value per annum [b] = 9,000, 95%
CI 5,000–13,000, p<0.001). Annual increases in the point
estimates of these discharges over the precedent year were
43%, 18%, and 27% in 2001, 2002, and 2003, respective-
ly, although the single year increases in 2002 and 2003
were not significant. Meanwhile, the number of discharges
for which CDAD was listed as any diagnosis nearly dou-
bled from 98,000 (95% CI 84,000–112,000) in 1996 to
178,000 (95% CI 151,000–205,000) in 2003 (b = 28,000,
95% CI 19,000–38,000, p<0.001). Annual increases in the
point estimates of these discharges over the preceding year
were 43%, 21%, and 5% in 2001, 2002, and 2003, respec-
tively; again, the only significant single-year increase was
in 2001. The estimated population-based rates of dis-
charges with either a first-listed or any diagnosis of CDAD
during this period are presented in Figure 1, along with the
95 CIs for these estimates. The upward trends in rates of
CDAD both as first-listed (b = 3.1, 95% CI 1.70–4.48, p =
0.008) and as any (b = 9.48, 95% CI 6.16–12.80, p = 0.01)
discharge diagnosis were significant between 2000 and
2003.
Based upon the estimated 250 million discharges from
1996 to 2003, the proportions of discharged patients with
CDAD listed as first or any diagnosis were 0.10% (95% CI
0.092–0.11%) and 0.38% (95% CI 0.35%–0.41%), respec-
tively. Both of these rates increased in a fashion similar to
that of population-based rates shown in Figure 1. For
CDAD as the first-listed discharge diagnosis, a significant
upward trend was evident, from 0.08% in 2000 to 0.16%
in 2003 (b = 0.024, 95% CI 0.014–0.0035, p = 0.02). For
CDAD as any discharge diagnosis, a significant upward
trend occurred from 0.27% in 2000 to 0.51% in 2003
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Figure 1. National estimates of US short-stay hospital discharges
with  Clostridium difficile listed as primary or as any diagnosis.
Isobars represent 95% confidence intervals.(b = 0.072, 95% CI 0.048–0.095, p = 0.009). Rates of any
CDAD discharge diagnosis over the entire study period
(1996–2003) are shown stratified by various demographic
factors in the Table; overall rates during this period were
identical in male and female discharged patients.  
However, the overall rate was severalfold higher in per-
sons >65 years of age than in persons ages 45–64 years,
and the rate in persons ages 45–64 years was in turn high-
er than rates in persons ages 15–44 years and persons ages
<15 years (Table). In addition, significant increasing trends
were found between 2000 and 2003 in both of the older
age groups; however, the slope of the increase was several
fold greater in those ages >65 years (b = 58.1, 95% CI
36.5–79.7, p = 0.01) than those ages 45–64 years (b = 7.9,
95% CI 4.0–11.7, p = 0.03) (Figure 2).
Regional rates of CDAD as any discharge diagnosis are
shown in Figure 3. Although rates appeared to increase in
each US region from 2000 to 2003, a significant linear
trend was found only for the Midwest (b = 13.1, 95% CI
5.4–20.8, p = 0.04) and South (b = 7.9, 95% CI 3.4–12.3,
p = 0.04). Overall, during 1996–2003, the rate of CDAD as
any discharge diagnosis was higher in the Northeast than
in the Midwest, South, and West (Table). 
The proportions of discharges, including CDAD as any
diagnosis, stratified according to hospital size, are shown
in Figure 4. Although rates appeared to increase in each
group, from 2000 to 2003, a significant linear trend was
found only for hospitals with 100 to 299 beds (b = 0.066,
95% CI 0.027–0.10, p = 0.04) and >300 beds (b = 0.070,
95% CI 0.04–0.10, p = 0.02). Overall rates for 1996–2003
were similar between hospitals with 100–299 beds and
hospitals with >300 beds, whereas rates in hospitals with
<100 beds were significantly lower than rates in either
group of larger sized hospitals (Table).
The absolute number of CDAD patients who were
transferred to a long-term care facility increased from
20,000 (95% CI 13,000–28,000) in 2000 to 57,000 (95%
CI 43,000–71,000) (b = 13,000, 95% CI 8,000–17,000, p =
0.01). CDAD discharges also accounted for an increasing
proportion of all patients who were transferred to long-
term care facilities during this period, rising from 0.78%
(95% CI 0.52–1.04) of long-term care transfers in 2000 to
1.87% (95% CI 1.48–2.26) in 2003 (b = 0.37, 95% CI
0.23–0.52, p = 0.01). Although the point estimate of
CDAD inpatients who died before discharge increased
from 8,000 (95% CI 5,000–12,000) in 2000 to 15,000
(95% CI 10,000–20,000 in 2003, this trend was not signif-
icant (b = 1,910, 95% CI 100–3,700, p = 0.1). Moreover,
the proportion of deaths among CDAD discharges did not
change significantly: 8.52% (95% CI 5.40–11.64) in 2000
to 8.39% (95% CI 6.09–10.69) in 2003 (b = 0.25, 95% CI
0.90–1.40, p = 0.70). 
Discussion
We found both the number and rate of US short-stay
hospital discharges with a diagnosis of CDAD increased
from 2000 through 2003. The overall rate and increase in
the number of discharges were most prominent among
patients >65 years of age. Although the overall rate was
highest in the Northeast, a significant linear increase was
found only in the Midwest and South. Rates increased sim-
ilarly in middle- and large-sized hospitals according to
number of beds, and overall rates were similar in these 2
strata; in contrast, small hospitals had a lower overall rate
and did not experience a significant increase. 
Our study had several limitations. We analyzed only
hospital discharge data and the sensitivity and specificity
of hospital discharge coding for CDAD are largely
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tinal infection with C. difficile” contains the organism
name, the code may be used on the basis of the clinical sus-
picion of CDAD alone, in some instances without a posi-
tive laboratory test result. In a single-institution study,
when the number of positive C. difficile laboratory results
were compared to the number of ICD-9-CM coded diag-
noses, ICD-9-CM diagnoses overestimated by 32% the
number of cases predicted by positive laboratory results
(16). However, a month-to-month correlation was found
between cases detected by a positive C. difficile laboratory
test result and ICD-9-CM coded diagnosis; when patient
medical records of these disparate cases (i.e., agreement
with ICD-9-CM code and negative for C. difficile labora-
tory results or not tested) were reviewed in detail, most had
a history of CDAD during a previous admission or had a
C. difficile laboratory test ordered that either had a nega-
tive result or was cancelled before specimen collection.
Another recent comparison of laboratory and ICD-9-CM
data from all US Veterans Affairs hospitals demonstrated
that ICD-9-CM coded diagnoses of CDAD underestimated
by approximately half the number of CDAD patient dis-
charges determined by positive laboratory results (17).
These investigators also confirmed that ICD-9-CM coded
diagnoses of CDAD correlated with the number of CDAD
patient discharges determined by positive laboratory
results, both among different hospitals as well as over time
within individual hospitals. 
Along with the potential insensitivity of coding, limita-
tions involve the sensitivity of commonly used diagnostic
tests for CDAD. Many hospital laboratories have migrated
away from performing culture for C. difficile (sensitive but
nonspecific for toxin-producing strains) or tissue culture
cytotoxin assays toward the performance of less time-con-
suming, but generally less sensitive, toxin immunoassays.
Data are available on diagnostic methods other than bacte-
rial culture collected as part of proficiency surveys con-
ducted by the College of American Pathologists (CAP)
between 1999 and 2003 (18). Responses from at least
2,250 North American clinical laboratories surveyed annu-
ally suggest that, from 1999 through 2003, <5% laborato-
ries overall performed tissue culture cytotoxin assays.
Although this proportion is small, even if it were much
larger, sensitivity could still be an issue as some evidence
has shown that even a tissue culture cytotoxin assay per-
formed directly on stool misses a large proportion of
patients with diarrhea and low numbers of cytotoxin-pro-
ducing C. difficile (19). 
One possible interpretation of our findings is that the
observed increase in CDAD reflects a migration away
from immunoassays that detect only toxin A toward use of
assays that detect toxin A and B after reports of fatal cases
associated with toxin A–negative and toxin B–positive
strains (20). Indeed, the data from CAP mentioned above
indicate such a trend: 78% of laboratories in 1999 per-
formed toxin A immunoassays only and 7% performed
toxin A and B immunoassays, whereas by 2003, 55% per-
formed toxin A only immunoassays, and 38% performed
toxin Aand B immunoassays (18). Although this change in
testing practices was gradual, even if it had been more sud-
den, the increased sensitivity of combined toxin A and B
immunoassays could not likely explain the observed
increase in rates between 2000 and 2003 because toxin A-
B–positive strains account for no more than 5% of C. dif-
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Figure 2. Rates of US short-stay hospital discharges with
Clostridium difficile listed as any diagnosis, by age. Isobars repre-
sent 95% confidence intervals. Because of low rates and the
resulting uncertainty of yearly rate estimates, data for patients <15
years of age are not included.
Figure 3. Rates of US short-stay hospital discharges with
Clostridium difficile listed as any diagnosis, by region. Northeast
(Connecticut, Maine, Massachusetts, New Hampshire, Rhode
Island, Vermont, New Jersey, New York, Pennsylvania), Midwest
(Indiana, Illinois, Michigan, Ohio, Wisconsin, Iowa, Kansas,
Minnesota, Missouri, Nebraska, North Dakota, South Dakota),
South (Delaware, Washington DC, Florida, Georgia, Maryland,
North Carolina, South Carolina, Virginia, West Virginia, Alabama,
Kentucky, Mississippi, Tennessee, Arkansas, Louisiana,
Oklahoma, Texas), and West (Arizona, Colorado, Idaho, New
Mexico, Montana, Utah, Nevada, Wyoming, Alaska, California,
Oregon, Washington, Hawaii) regions as defined by US Census
Bureau.ficile isolates (21). Nonetheless, to address this issue as
well as the possibility that more CDAD cases were being
diagnosed due to increased C. difficile testing, we analyzed
rates of diarrhea using ICD-9-CM codes for nonspecific
causes and found no significant decrease. This suggests
that the observed increases in CDAD were not simply due
to diagnosing more disease among patients with diarrhea
of nonspecific causes (data not shown). 
Our findings suggest a large impact of excess illness and
costs posed by CDAD on the US healthcare system; an
impact that may approach or exceed that caused by other
more widely recognized nosocomial pathogens. For exam-
ple, the number of US short-stay hospital discharge diag-
noses of CDAD during 2001, 2002, or 2003 exceeded the
estimated annual number (120,000) of methicillin-resistant
Staphylococcus aureus (MRSA) infections for 1999–2000
(22). Kyne et al. recently estimated that each case of CDAD
in their hospital was associated with $3,699 in excess
healthcare costs and 3.6 extra days of hospitalization (7).
Based upon their hospital’s rate of CDAD in 0.7% of dis-
charges, they estimated that the total excess in US health-
care costs attributable to CDAD was likely >$1.1 billion.
Even using our lower estimate for the total US cases in
2003 (i.e., 0.51% or 178,000), CDAD can be estimated to
have resulted in >$600 million in excess healthcare costs
and >600,000 excess hospital days in nonfederal facilities.
However, such estimates only account for resource use in
short-stay hospitals. Even though some residents infected
in long-term care facilities receive their treatment in short-
stay facilities, these estimates of excess healthcare costs do
not account for the infection control and medication costs
incurred within long-term care facilities.
Although our findings are consistent with a recent
analysis of CDAD rates in NNIS hospitals (12), our results
highlight 2 new and unique developments in the epidemi-
ology of this disease. Archibald et al. described a gradual
increasing trend between 1987 and 2001 in ICU rates from
hospitals with >500 beds and in hospitalwide rates from
hospitals with <250 beds (12). We found a sharp increase
in hospitalwide rates during 2001–2003 following steady
rates from 1996 to 2000; this increase was similar in medi-
um and large hospitals. In contrast to early results from
NNIS during the spread of MRSA (23), when rates were
highest in hospitals with the greatest number of beds, we
found that overall rates of CDAD were similar in medium
and large hospitals.
Several possible explanations may account for the
increasing national rates of CDAD. One includes poten-
tially new and evolving patterns of antimicrobial drug use,
for example, use of the fluoroquinolones that have recent-
ly been implicated in outbreaks of CDAD (9,24,25).
Another potential contributing factor is the promotion of
alcohol-based, waterless, hand sanitizers as the primary
means of hand hygiene over soap and water. Because alco-
hol is not sporicidal, alcohol-based, waterless hand sanitiz-
ers may not be as effective as soap and water in removing
C. difficile; this factor has led to the recommendation that
“during outbreaks of CDAD, washing hands with a nonan-
timicrobial [agent] or antimicrobial soap and water after
removing gloves is prudent”(26). 
One important possibility is the emergence of strains of
C. difficile that are more fit and capable of causing trans-
mission and disease. This emergence would not be
unprecedented; in the early 1990s a strain of C. difficile
that was clindamycin resistant, the so-called “J strain,”
caused outbreaks in at least 5 geographically diverse hos-
pitals (5,27). Indeed, a recent report suggests that an
emerging fluoroquinolone-resistant, epidemic strain of C.
difficile has been responsible for hospital outbreaks in at
least 6 US states (Georgia, Illinois, New Jersey, Maine,
Oregon, Pennsylvania) since 2001 (28). This epidemic
strain has continued to spread among additional US states
(Connecticut, Florida, Massachusetts, Ohio, Texas),
Canada, and Europe (29). Another recent report suggests
this strain produces 16- and 23-fold more toxins A and B,
respectively, than current nonepidemic strains (30).
Depending on where the earliest outbreaks caused by this
epidemic strain were reported, the higher overall rates in
the northeastern United States may reflect the early spread
of this strain (9,10,28,29). If this hypothesis proves cor-
rect, it suggests other regions of the United States are like-
ly to observe continued increases as the strain continues to
spread geographically. 
One striking finding we report is the marked variation
in CDAD rates among different age groups, with rates in
persons >65 years of age several fold higher than rates in
the next younger age group (45–64 years). Although the
importance of advanced age as a risk for CDAD is not a
new idea (1,3), this is the first report of national CDAD
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Figure 4. Proportion of US short-stay hospital discharges with
Clostridium difficile listed as any diagnosis, by hospital size (num-
ber of beds).rates according to age group. Several possible reasons may
explain this association between CDAD and age, not the
least of which is increased exposure to healthcare facilities
(including both acute and long-term facilities) and antimi-
crobial drugs. In addition, older persons may have
decreased host defenses to protect them from CDAD.
These conditions include decreased stomach acidity result-
ing from achlorhydria or a possibly increased use of med-
ications such as histamine-2 receptor blockers or
proton-pump inhibitors, medications that are becoming
increasingly recognized in association with CDAD
(31,32). Recent evidence also suggests the importance of a
humoral immune response in protecting against CDAD
after colonization (33–37). Thus, the decreased immune
responsiveness commonly observed in older groups may
be important in the development of CDAD in patients >65
years of age. 
Contact precautions are recommended to prevent trans-
mission of C. difficile in the healthcare setting (38). These
consist of placing patients with CDAD in private rooms or
cohorting CDAD patients together, using gloves and
gowns for all patient contact, and either using disposable
patient care equipment or cleaning such equipment
between use with different patients. In addition, removing
certain potential fomites, such as reusable electronic ther-
mometers, from use in the general hospital patient popula-
tion is important for controlling outbreaks (1). Limited
data support enhanced environmental cleaning, especially
of heavily contaminated patient care equipment. Clinicians
should be aware of the importance of adhering to these
precautions for containing transmission of CDAD in
healthcare facilities. However, because antimicrobial drug
use is the single most important patient risk factor, the clin-
ician’s primary responsibility in the control of CDAD lies
in the area of judicious antimicrobial drug use (1).
In conclusion, the overall scope and magnitude of
CDAD are great and may exceed those of other important
hospital pathogens (e.g., MRSA), which suggests that C.
difficile is one of the most common nosocomial pathogens.
In addition, the financial costs and patient illness caused
by CDAD in US short-stay hospitals appear substantial.
Patients >65 years of age and those in intermediate- or
larger-sized hospitals appear disproportionately affected.
Because rates appear to have markedly increased during
the first 3 years of this decade, new initiatives in the areas
of surveillance, prevention, and control of CDAD are
urgently needed. In the meantime, clinicians should be
aware of the risk posed by CDAD in their hospitalized
patients, remain cognizant of the importance of judicious
antimicrobial drug use, and support infection control
efforts for CDAD in the healthcare settings where they
practice. 
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Aspergillus
Genus of filamentous, ubiquitous fungi, commonly isolated from soil, plant
debris, and indoor air. Aspergillus was first described in 1729 by Pier Antonio
Micheli, an Italian priest and biologist who was the first person to attempt the sci-
entific study of fungi. Micheli opposed the idea of "spontaneous generation" by
showing that fungal spores grown on a medium would produce the same kind of
fungus. The shape of Aspergillus reminded him of an aspergillum (from the Latin
aspergere, "to scatter"), a device used for sprinkling holy water during a liturgi-
cal service.
Sources: Dorland's illustrated medical dictionary. 30th ed. Philadelphia: Saunders; 2003
and the Illinois Mycological Association, available from http://www.ilmyco.gen.chicago.il.us/
e et ty ym mo ol lo og gi ia a
Conidiophore of Aspergillus fumigatus.
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